<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d357">
    <sentence id="DDI-DrugBank.d357.s0" text="5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .">
        <entity id="DDI-DrugBank.d357.s0.e0" charOffset="0-15"
            type="group" text="5HT3 Antagonists"/>
        <entity id="DDI-DrugBank.d357.s0.e1" charOffset="90-100"
            type="drug" text="apomorphine"/>
        <entity id="DDI-DrugBank.d357.s0.e2" charOffset="124-134"
            type="drug" text="ondansetron"/>
        <entity id="DDI-DrugBank.d357.s0.e3" charOffset="160-170"
            type="drug" text="apomorphine"/>
        <entity id="DDI-DrugBank.d357.s0.e4" charOffset="190-210"
            type="group" text="5HT3 antagonist class"/>
        <entity id="DDI-DrugBank.d357.s0.e5" charOffset="237-247"
            type="drug" text="ondansetron"/>
        <entity id="DDI-DrugBank.d357.s0.e6" charOffset="250-260"
            type="drug" text="granisetron"/>
        <entity id="DDI-DrugBank.d357.s0.e7" charOffset="263-272"
            type="drug" text="dolasetron"/>
        <entity id="DDI-DrugBank.d357.s0.e8" charOffset="275-286"
            type="drug" text="palonosetron"/>
        <entity id="DDI-DrugBank.d357.s0.e9" charOffset="293-301"
            type="drug" text="alosetron"/>
        <ddi id="DDI-DrugBank.d357.s0.d0" e1="DDI-DrugBank.d357.s0.e1"
            e2="DDI-DrugBank.d357.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d357.s0.d1" e1="DDI-DrugBank.d357.s0.e3"
            e2="DDI-DrugBank.d357.s0.e4" type="advise"/>
        <ddi id="DDI-DrugBank.d357.s0.d2" e1="DDI-DrugBank.d357.s0.e3"
            e2="DDI-DrugBank.d357.s0.e5" type="advise"/>
        <ddi id="DDI-DrugBank.d357.s0.d3" e1="DDI-DrugBank.d357.s0.e3"
            e2="DDI-DrugBank.d357.s0.e6" type="advise"/>
        <ddi id="DDI-DrugBank.d357.s0.d4" e1="DDI-DrugBank.d357.s0.e3"
            e2="DDI-DrugBank.d357.s0.e7" type="advise"/>
        <ddi id="DDI-DrugBank.d357.s0.d5" e1="DDI-DrugBank.d357.s0.e3"
            e2="DDI-DrugBank.d357.s0.e8" type="advise"/>
        <ddi id="DDI-DrugBank.d357.s0.d6" e1="DDI-DrugBank.d357.s0.e3"
            e2="DDI-DrugBank.d357.s0.e9" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d357.s1" text="Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.">
        <entity id="DDI-DrugBank.d357.s1.e0" charOffset="0-26"
            type="group" text="Antihypertensive Medication"/>
        <entity id="DDI-DrugBank.d357.s1.e1" charOffset="33-44"
            type="group" text="Vasodilators"/>
        <entity id="DDI-DrugBank.d357.s1.e2" charOffset="141-168"
            type="group" text="antihypertensive medications"/>
        <entity id="DDI-DrugBank.d357.s1.e3" charOffset="173-184"
            type="group" text="vasodilators"/>
        <ddi id="DDI-DrugBank.d357.s1.d0" e1="DDI-DrugBank.d357.s1.e2"
            e2="DDI-DrugBank.d357.s1.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d357.s2" text="The mechanism underlying many of these events is unknown, but may represent increased hypotension ."/>
    <sentence id="DDI-DrugBank.d357.s3" text="Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.">
        <entity id="DDI-DrugBank.d357.s3.e0" charOffset="0-19"
            type="group" text="Dopamine Antagonists"/>
        <entity id="DDI-DrugBank.d357.s3.e1" charOffset="28-38"
            type="drug" text="apomorphine"/>
        <entity id="DDI-DrugBank.d357.s3.e2" charOffset="45-60"
            type="group" text="dopamine agonist"/>
        <entity id="DDI-DrugBank.d357.s3.e3" charOffset="83-102"
            type="group" text="dopamine antagonists"/>
        <entity id="DDI-DrugBank.d357.s3.e4" charOffset="117-128"
            type="group" text="neuroleptics"/>
        <entity id="DDI-DrugBank.d357.s3.e5" charOffset="131-144"
            type="group" text="phenothiazines"/>
        <entity id="DDI-DrugBank.d357.s3.e6" charOffset="147-160"
            type="group" text="butyrophenones"/>
        <entity id="DDI-DrugBank.d357.s3.e7" charOffset="163-175"
            type="group" text="thioxanthenes"/>
        <entity id="DDI-DrugBank.d357.s3.e8" charOffset="181-194"
            type="drug" text="metoclopramide"/>
        <entity id="DDI-DrugBank.d357.s3.e9" charOffset="231-236"
            type="brand" text="APOKYN"/>
        <ddi id="DDI-DrugBank.d357.s3.d0" e1="DDI-DrugBank.d357.s3.e3"
            e2="DDI-DrugBank.d357.s3.e8" type="effect"/>
        <ddi id="DDI-DrugBank.d357.s3.d1" e1="DDI-DrugBank.d357.s3.e5"
            e2="DDI-DrugBank.d357.s3.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d357.s3.d2" e1="DDI-DrugBank.d357.s3.e6"
            e2="DDI-DrugBank.d357.s3.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d357.s3.d3" e1="DDI-DrugBank.d357.s3.e7"
            e2="DDI-DrugBank.d357.s3.e9" type="effect"/>
        <ddi id="DDI-DrugBank.d357.s3.d4" e1="DDI-DrugBank.d357.s3.e8"
            e2="DDI-DrugBank.d357.s3.e9" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d357.s4" text="Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.">
        <entity id="DDI-DrugBank.d357.s4.e0" charOffset="54-65"
            type="group" text="neuroleptics"/>
        <entity id="DDI-DrugBank.d357.s4.e1" charOffset="91-107"
            type="group" text="dopamine agonists"/>
        <ddi id="DDI-DrugBank.d357.s4.d0" e1="DDI-DrugBank.d357.s4.e0"
            e2="DDI-DrugBank.d357.s4.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d357.s5" text="Drugs Prolonging the QT/QTc Interval Caution should be exercised when prescribing apomorphine concomitantly with drugs that prolong the QT/QTc interval.">
        <entity id="DDI-DrugBank.d357.s5.e0" charOffset="82-92"
            type="drug" text="apomorphine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d357.s6" text="Drug/Laboratory Test Interactions There are no known interactions between APOKYN and laboratory tests.">
        <entity id="DDI-DrugBank.d357.s6.e0" charOffset="74-79"
            type="brand" text="APOKYN"/>
    </sentence>
</document>
